COVID-19与全身性炎症有关联。这种炎症反应在恶性肿瘤治疗中进一步被破坏，从而增加了这一人群的死亡率。然而，关于严重COVID-19患者死亡率增加的临床因素存在冲突的信息。本研究旨在确定与活动性癌症患者严重COVID-19病情死亡率相关的预后因素。此外，还评估了与严重COVID-19相关的肿瘤学代码与死亡率之间的相关性。我们分析了2020年3月至2021年2月间患有活动性癌症和严重COVID-19的墨西哥患者队列。我们收集了关于患者人口统计学特征，COVID-19症状，临床和实验室数据，以及治疗情况的信息。根据肿瘤学代码对患者进行了分类。我们基于临床分期，治疗意图，COVID-19前的疗效状况以及姑息治疗的中位总生存期定义了肿瘤学代码。进行对数秩和检验以确定生存情况。使用多元逻辑回归模型进行潜在混杂因素的调整。共有152例严重COVID-19患者进行了分析。红色肿瘤学代码与死亡风险增加有关，OR为22.8（CI 95％ 5.0-105.1，p <0.001），低氧饱和度OR为5.4（CI 95％ 1.7-17.4，p = 0.005），慢性类固醇使用OR为4.3（CI 95％ 1.0-18.1，p = 0.050），高D-二聚体水平OR为3.2（CI 95％ 1.2-8.2，p = 0.019）。可以通过纳入入院时的特定肿瘤学特征确定活动性癌症患者严重COVID-19的生存情况。根据此代码，降低的氧饱和度，增加的D-二聚体水平和慢性类固醇使用是与死亡相关的主要预测因素。版权所有 © 2023，由Elsevier Inc. 发布。

COVID-19 is associated with systemic inflammation. This inflammatory response is further deregulated by oncological treatments increasing mortality in this population. However, there is conflicting information regarding the clinical factors that increase mortality in patients with severe COVID-19.The aim of this study was to identify prognostic factors associated with mortality during severe COVID-19 in patients with active cancer. In addition, the correlation between oncologic codes and mortality related to severe COVID-19 was evaluated.We analyzed a cohort of Mexican patients with active cancer and severe COVID-19 between March 2020 and February 2021. We collected information on patient demographic characteristics, COVID-19 symptoms, clinical and laboratory data, and treatments. Patients were classified according to oncologic code. We defined the oncological code based on clinical stage, treatment intention, performance status before COVID-19, and median overall survival with palliative treatment. A log-rank test was performed to determine survival. A multivariate logistic regression model was used to adjust for potential confounders.One hundred fifty-two patients with severe COVID-19 were analyzed. The red oncologic code was associated with an increased risk of mortality OR 22.8 (CI 95% 5.0-105.1, p <0.001), low oxygen saturation OR 5.4 (CI 95% 1.7-17.4, p = 0.005), chronic corticosteriod use OR 4.3 (CI 95% 1.0-18.1, p = 0.050) and high D-dimer level OR 3.2 (CI 95% 1.2-8.2, p = 0.019).The survival of patients with active cancer and severe COVID-19 was possible to identify, at the time of admission, specific oncological characteristics. Based on this code, decreased oxygen saturation, increased D-dimer levels, and chronic corticosteroid use were the main predictive factors related to mortality.Copyright © 2023. Published by Elsevier Inc.